Funding Agreement Sets Stage for New Growth Opportunities and
Clinical Programs

LOS ANGELES, CA -- (Marketwired) -- 07/15/16 --  Endonovo
Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a
developer of bioelectronic devices and medicines, announced today
that it has entered into a funding agreement with an institutional
investor to provide up to an aggregate of $10 million in financing
consisting of (a) $1 million in Convertible Notes (the "Notes"), of
which $400,000 has been received to date, and (b) up to $9 million in
financing through a Securities Purchase Agreement (the "SPA").

The Notes consist of $400,000 on the effective date of the agreement,
$200,000 within 30 days of the effective date, and $400,000 upon a
registration statement being declared effective by the Securities and
Exchange Commission (SEC).

The Securities Purchase Agreement provides up to $9 million in
aggregate financing and is subject to an S-1 Registration Statement
being declared effective by the Securities and Exchange Commission
(SEC) which is to be filed in shortly. The $9,000,000 Equity Line is
pursuant to an Equity Line Securities Purchase Agreement ("ELSPA")
that provides for a 3% origination fee and also requires the provider
to purchase shares of our stock which we will put at a price equal to
75% of the lowest bid price for our stock during the 20 trading days
preceding the put notice. The SPA has a 36-month term and allows the
Company to drawdown, at its discretion, on the facility, based on the
timing and volume provisions set forth in the agreement.

Endonovo Therapeutics will, as necessary, use the proceeds from this
new round of financing to fund general corporate expenses, research
and development on its bioelectronic platforms, and to complete the
acquisition of Rio Grande Neurosciences.

More information regarding the Convertible Notes and the Securities
Purchase Agreement and the terms and conditions thereof will be
disclosed in the Current Report on Form 8-K to be filed by Endonovo
today with the Securities and Exchange Commission.

This press release shall not constitute an offer to sell or the
solicitation of an offer to acquire any securities, nor shall there
be any sale of any securities in any state or other jurisdiction in
which such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is an innovative biotechnology company
developing bioelectronic devices and medicines. Endonovo's
Immunotronics(TM) platform is a non-invasive, non-implantable
bioelectronic device for treating/preventing vital organ failure
through the reduction of inflammation and cell death and the
promotion of regeneration. Endonovo's Cytotronics(TM) platform
provides for a method of expanding and optimizing the therapeutic
potential of stem cells using simulated microgravity and Time-Varying
Electromagnetic Fields (TVEMF) for tissue engineering and cell
therapies. The Company's initial concentration is on the treatment of
acute and chronic inflammatory conditions of the liver using its
proprietary Immunotronics(TM) platform.

Investors: Sign Up for Email Alerts on Endonovo

Safe Harbor Statement

This press release contains information that constitutes
forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
All statements, trends, analysis, and other information contained in
this press release including words such as "anticipate," "believe,"
"plan," "estimate," "expect," "intend," and other similar expressions
of opinion, constitute forward-looking statements. Any such
forward-looking statements involve risks and uncertainties that could
cause actual results to differ materially from any future results
described within the forward-looking statements. Risk factors that
could contribute to such differences include those matters more fully
disclosed in the Company's reports filed with the Securities and
Exchange Commission. The forward-looking information provided herein
represents the Company's estimates as of the date of the press
release, and subsequent events and developments may cause the
Company's estimates to change. The Company specifically disclaims any
obligation to update the forward-looking information in the future.
Therefore, this forward-looking information should not be relied upon
as representing the Company's estimates of its future financial
performance as of any date subsequent to the date of this press

Endonovo Therapeutics, Inc.
Investor Relations Contact:
Mr. Steven Barnes
Senior Vice President of Investor Relations
(800) 701-1223, Ext. 108